Aeglea BioTherapeutics
expected interim data will also inform our ability to test induction exposure response relationship in phase | Aeglea BioTherapeutics
Company
Deck Type
Sector
Industry
Deck date
October 2023
Slide
16 of 38
Similar slides by Aeglea BioTherapeutics
See diffirences between slides (animation)
Investor Presentation
October 2023
expected interim data will also inform our ability to test induction exposure response relationship in phase | Aeglea BioTherapeutics
Related slides by other companies
ATAI
Investor Presentation
October 2023
in cash as of provides expected runway into life sciences operational focus program guidance | ATAI
ATAI
Investor Presentation
March 2023
achieved and expected milestones phase data phase data phase first subject dosed phase data anorexia key achievements to date phase data phase data initiation of clinical programs phase data phase a data phase data phase data phase data summer phase study data in cash as of plus access to up to an additional from term loan facility provides runway expected into we expect deliver several meaningful anticipated across our through with | ATAI
Ocuphire Pharma
Investor Day
January 2022
phase clinical trials data supporting the zeta trial rat aches high levels in rat eye is orally | Ocuphire Pharma
BAT
Results
July 2020
quantum the benefits of phase at | BAT
Other recent decks by Aeglea BioTherapeutics
See all presentations (14 decks)
Investor Presentation
October 2023
Investor Presentation
September 2023
Investor Presentation
July 2023
Mergers and Acquisitions
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io